Beihai Kangcheng-B (01228.HK) announced that according to top-line data from the CAN008 phase II clinical trial for newly diagnosed glioblastoma patients, CAN008 provided no additional benefit compared to placebo in terms of progression-free survival or overall survival in patients receiving standard treatment with temozolomide and radiotherapy.
北海康成-B(01228.HK)决定终止CAN008在胶质母细胞瘤领域的研发及进一步试验
Beihai Kangcheng-B (01228.HK) decided to discontinue development and further testing of CAN008 in the field of glioblastoma
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.